![]() Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. | ![]() Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. | ![]() Viatris Viatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products. | |
Founding Date | Founding Date 1923 | Founding Date 2016 | Founding Date 2020 |
Type | Type Public | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Irvine, US HQ Basel, CH | Locations Canonsburg, US HQ Carole Park, AU Millers Point, AU Campos Dos Goytacazes, BR São Paulo, BR Sofia, BG Toronto, CA see more |
Employees | Employees 14,754 | Employees 3950% increase | Employees 38,0003% increase |
Valuation ($) | Valuation ($) 20.8 b | Valuation ($) N/A | Valuation ($) 14 b |
Financial | |||
Revenue (est.) | Revenue (est.) ¥1.9t (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $14.7b (FY, 2024) |
Cost of goods | Cost of goods ¥150.1b (FY, 2025) | Cost of goods N/A | Cost of goods $9.1b (FY, 2024) |
Gross profit | Gross profit ¥1.8t (FY, 2025) | Gross profit N/A | Gross profit $5.6b (FY, 2024) |
Net income | Net income ¥50.7b (FY, 2025) | Net income ($146.7m) (FY, 2020) | Net income ($634.2m) (FY, 2024) |
Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions.
View companyViatris is a pharmaceutical company that develops and manufactures branded and generic medicines, biosimilar medicines, and over-the-counter products.
View company